Recovery research fieldbook Evidence, not treatment advice
Recovery archive

Published recovery field note

Stable gastric pentadecapeptide BPC 157 in trials for

. 2007;37(9):768-77. doi: 10.1007/s00595-006-3498-9. Epub 2007 Aug 27. Ivan Zoricic, Luka Brcic, Marko Sever, Robert Klicek, Bozo Radic, Vedran Cesarec, Lidija Berkopic, Neike Keller, Alenka Boban Blagaic, Neven Kokic, Ivan Jelic, Juraj Geber, Tomislav Anic, Sven Seiwerth, Predrag Sikiric Affiliations PMID: 17713731 DOI: 10.1007/s00595-006-3498-9 Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL14736, Pliva, Croatia) heals ileoileal anastomosis in the rat Tihomir Vuksic et al. Surg Today. 2007. Abstract Purpose: Gastric pentadecapeptide BPC 157 (BPC 157), which has been shown to be safe in clinical trials for inflammatory bowel disease (PL-10, PLD-116, PL14736, Pliva, Croatia), may be able to cure intestinal anastomosis dehiscence. This antiulcer peptide shows no toxicity, is limit test negative, and a lethal dose is not achieved. It is stable in human gastric juice. In comparison with other standard treatments it is more effective for

Context first

Study findings do not automatically establish clinical benefit, safety, dosing, or suitability for an individual.

. 2007;37(9):768-77.

doi: 10.1007/s00595-006-3498-9. Epub 2007 Aug 27.

Ivan Zoricic, Luka Brcic, Marko Sever, Robert Klicek, Bozo Radic, Vedran Cesarec, Lidija Berkopic, Neike Keller, Alenka Boban Blagaic, Neven Kokic, Ivan Jelic, Juraj Geber, Tomislav Anic, Sven Seiwerth, Predrag Sikiric

Affiliations

PMID: 17713731 DOI: 10.1007/s00595-006-3498-9

Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL14736, Pliva, Croatia) heals ileoileal anastomosis in the rat

Tihomir Vuksic et al. Surg Today. 2007.

Abstract

Purpose: Gastric pentadecapeptide BPC 157 (BPC 157), which has been shown to be safe in clinical trials for inflammatory bowel disease (PL-10, PLD-116, PL14736, Pliva, Croatia), may be able to cure intestinal anastomosis dehiscence. This antiulcer peptide shows no toxicity, is limit test negative, and a lethal dose is not achieved. It is stable in human gastric juice. In comparison with other standard treatments it is more effective for ulcers and various wounds, and can be used without a carrier needed for other peptides, both locally and systemically (i.e., perorally, parenterally). We studied the effectiveness of BPC 157 for ileoileal anastomosis healing in rats.

Methods: We assessed ileoileal anastomosis dehiscence macroscopically, histologically, and biomechanically (volume [ml] infused through a syringe-perfusion pump system (1 ml/10 s), and pressure [mmHg] to leak induction [catheter connected to a chamber and a monitor, at 10 cm proximal to anastomosis]), at 1, 2, 3, 4, 5, 6, 7, and 14 days. BPC 157 (10 microg, 10 ng, 10 pg/kg i.p. (or saline [5 ml/kg]) was first administered after surgery, while it was last given 24 h before either assessment or sacrifice.

Results: Throughout the experiment, both higher doses of BPC 157 were shown to improve all parameters of anastomotic wound healing. The formation of adhesions remained slight, the blood vessels were filled with blood, and a mild intestinal passage obstruction was only temporarily observed. Anastomosis without leakage induces markedly higher volume and pressure values, with a continuous increase toward healthy values. From day 1, edema was markedly attenuated and the number of granulocytes decreased, while from days 4 or 5 necrosis decreased and granulation tissue, reticulin, and collagen formation substantially increased, thus resulting in increased epithelization.

Conclusion: This study showed BPC 157 to have a beneficial effect on ileoileal anastomosis healing in the rat.

PubMed Disclaimer

References

World J Surg. 1998 Oct;22(10):1069-75; discussion 1076 - PubMed

J Surg Res. 1997 Jun;70(1):84-8 - PubMed

Acta Chir Belg. 2004 Apr;104(2):198-203 - PubMed

J Pharmacol Sci. 2004 May;95(1):19-26 - PubMed

Science. 1987 Sep 11;237(4820):1333-6 - PubMed

Connected topics

Follow this recovery question